Medexus Pharmaceuticals (TSE:MDP) Stock Rating Upgraded by Leede Financial

Medexus Pharmaceuticals (TSE:MDP) was upgraded by equities research analysts at Leede Financial from a “moderate buy” rating to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports. Leede Financial also issued estimates for Medexus Pharmaceuticals’ FY2025 earnings at $0.29 EPS, FY2027 earnings at $0.69 EPS and FY2028 earnings at $1.30 EPS.

Several other research firms have also issued reports on MDP. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Ventum Cap Mkts raised Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 17th. Stifel Nicolaus lifted their price target on Medexus Pharmaceuticals from C$4.15 to C$4.50 in a report on Tuesday, January 14th. Finally, Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price objective on the stock in a report on Wednesday, January 8th. One research analyst has rated the stock with a buy rating and five have given a strong buy rating to the company. According to data from MarketBeat.com, Medexus Pharmaceuticals presently has an average rating of “Strong Buy” and an average target price of C$5.58.

Medexus Pharmaceuticals Stock Performance

Shares of MDP stock opened at C$4.47 on Wednesday. Medexus Pharmaceuticals has a 52-week low of C$1.47 and a 52-week high of C$5.56. The stock has a market cap of C$109.65 million, a price-to-earnings ratio of 89.40 and a beta of 1.96. The firm’s 50-day moving average is C$3.14 and its 200-day moving average is C$2.69.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.